

To: Ron Feakes



Date: June 1 1990


cc: David Galliford

From: Ivan Bryant

Subject: Draft Reply to Dr. Rafferty's Note

As requested please find attached a draft response to Patrick's memo of 21/5/90. If you have any queries give me a call.

Regards,   
GRO-CIvan Bryant 



To: Ron Feakes - Thetford

Date: 21 May 1990

From: Patrick Rafferty

Ron

In my capacity as Medical Director in order to understand more fully the clinical management of Haemophilia patients and the potential role for highly purified products in the control of their haemostasis, I have met with most of the Haemophilia Centre Directors in the past few months.

Following these meetings I have received a number of enquires relating to the effects of monoclonally purified Factor VIII:C on the levels of Hepatitis C antibodies in patients. It would appear that there is a relationship between the progression of Hepatic Cirrhosis and the levels of Hepatitis C antibodies in some patients. If this relationship exists, and if monoclonally purified Factor VIII:C is confirmed as being effective in significantly reducing or eliminating the levels of Hepatitis C antibody in these patients, then as Medical Director I have a moral obligation to bring this to the attention of the clinical experts who are responsible for the management of Haemophilia patients.

My understanding is that the Baxter monoclonally purified Factor VIII:C, Hemofil M, is currently not yet licenced in the UK - perhaps you could advise me on the most ethical approach for me to take in this regard, whilst meeting appropriate regulatory requirements.

Also as a result of meetings with Haemophilia Centre Directors. I have been asked about availability of product etc. Perhaps you could give me some guidance as to how I should handle such commercial issues, especially since Hemofil M is not yet a licenced product.

Many thanks for your help.

GRO-C

Patrick Rafferty  
Medical Director

VJB/486

B02

SHPL0000293\_141\_0002